Hydra Biosciences

Like many of its large pharma peers, Boehringer Ingelheim GmbH likes to talk about its lofty research and development goals and sourcing external innovation to stay on the cutting edge of therapeuti

Like many of its large pharma peers, Boehringer Ingelheim likes to talk about its lofty research and development goals and sourcing external innovation to stay on the cutting edge of therapeutic mod

Merck & Co., Inc. is in better shape now than it was in 2013 when Roger Perlmutter rejoined the big pharma as president of Merck Research Laboratories, largely because of the mega-blockbuster Keytrud

In an exclusive interview with Scrip at the BIO-Europe partnering conference in Berlin, Nov. 6-8, Klaus Mendla, Boehringer Ingelheim GMBH's global head of business development and licensing, CNS,